BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10837965)

  • 1. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
    Fields MT; Eisbruch A; Normolle D; Orfali A; Davis MA; Pu AT; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):785-91. PubMed ID: 10837965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.
    Braakhuis BJ; van Dongen GA; Vermorken JB; Snow GB
    Cancer Res; 1991 Jan; 51(1):211-4. PubMed ID: 1988086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
    Ostruszka LJ; Shewach DS
    Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.
    Joschko MA; Webster LK; Groves J; Yuen K; Palatsides M; Ball DL; Millward MJ
    Radiat Oncol Investig; 1997; 5(2):62-71. PubMed ID: 9303059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
    Eisbruch A; Shewach DS; Bradford CR; Littles JF; Teknos TN; Chepeha DB; Marentette LJ; Terrell JE; Hogikyan ND; Dawson LA; Urba S; Wolf GT; Lawrence TS
    J Clin Oncol; 2001 Feb; 19(3):792-9. PubMed ID: 11157033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.
    Lawrence TS; Davis MA; Hough A; Rehemtulla A
    Clin Cancer Res; 2001 Feb; 7(2):314-9. PubMed ID: 11234886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing therapeutic gain with gemcitabine and fractionated radiation.
    Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells.
    Robinson BW; Im MM; Ljungman M; Praz F; Shewach DS
    Cancer Res; 2003 Oct; 63(20):6935-41. PubMed ID: 14583494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.
    Shewach DS; Hahn TM; Chang E; Hertel LW; Lawrence TS
    Cancer Res; 1994 Jun; 54(12):3218-23. PubMed ID: 8205542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma.
    Jones PD; de Lorimier LP; Kitchell BE; Losonsky JM
    J Am Anim Hosp Assoc; 2003; 39(5):463-7. PubMed ID: 14518654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine).
    Lawrence TS; Chang EY; Hahn TM; Shewach DS
    Clin Cancer Res; 1997 May; 3(5):777-82. PubMed ID: 9815749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.
    Hoffmann W; Belka C; Schmidberger H; Budach W; Bochtler H; Hess CF; Bamberg M
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):691-6. PubMed ID: 9240634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.
    Lawrence TS; Chang EY; Hahn TM; Hertel LW; Shewach DS
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):867-72. PubMed ID: 8598364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
    Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late DNA Damage Mediated by Homologous Recombination Repair Results in Radiosensitization with Gemcitabine.
    Im MM; Flanagan SA; Ackroyd JJ; Knapp B; Kramer A; Shewach DS
    Radiat Res; 2016 Nov; 186(5):466-477. PubMed ID: 27740890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
    Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
    Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas.
    Chauhan A; Singh H; Sharma T; Manocha KK
    Afr Health Sci; 2008 Sep; 8(3):149-55. PubMed ID: 19357741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.
    Robinson BW; Shewach DS
    Clin Cancer Res; 2001 Aug; 7(8):2581-9. PubMed ID: 11489842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
    Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.